Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer

Inclusion Histologically confirmed newly diagnosed hepatoblastoma * Standard risk hepatoblastoma (Pretext I,II,III) * Age ≤ 18 years and \> 1 month * Written informed consent and national/local ethics committee and regulatory approval * Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done * Ability to comply with requirements for submission of material for central review * For females of child-bearing potential, a negative pregnancy test prior to study treatment is required. * Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial. Exclusion: High risk hepatoblastoma * Hepatocellular carcinoma * Treatment starting more than 15 days from written biopsy report * Abnormal renal function * Any previous chemotherapy * Recurrent disease * Previous hypersensitivity to STS * Patient unable to follow the protocol for any reason